An ISO-accredited research facility specialising in the next generation sequencing of liquid biopsies
The Oxford Molecular Diagnostics Centre (OMDC) is an Oxford University (OU) ISO-accredited research facility based on the John Radcliffe site at the Oxford University Hospitals Foundation Trust (OUH). It aims to develop, technically validate and clinically evaluate precision clinical genetics assays for early detection, treatment response/monitoring and risk stratification of patients with blood diseases and cancer. Doing so in a clinically accredited (ISO15189) NHS environment using liquid biopsies and other technologies, which allows the efficient, safe and cost effective development of novel clinical tests for direct clinical implementation into patient care pathways.
The MDC works in partnership with commercial pharmaceutical/diagnostic/biotech companies, academic groups and national clinical trial groups to enable them to fast-track their novel diagnostic strategies into novel molecular tests that can affect the clinical decision.
More information about our track record, capabilities, what we can offer both academic and commercial partners, and how to contact us with potential new projects can found on the Cancer Centre website.